NASDAQ: DRIODariohealth Corp Stock
$1.87+0.07 (+3.89%)
Updated Dec 8, 2023
DRIO Price
$1.87
Fair Value Price
$3.28
Market Cap
$50.89M
52 Week Low
$0.68
52 Week High
$6.78
P/E
-0.92x
P/B
0.75x
P/S
4.01x
PEG
N/A
Dividend Yield
N/A
Revenue
$23.55M
Earnings
-$57.76M
Gross Margin
36.5%
Operating Margin
-245.3%
Profit Margin
-258.6%
Debt to Equity
0.57
Operating Cash Flow
-$31M
Beta
1.07
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
DRIO Overview
DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario's metabolic solutions to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Musculoskeletal, which helps to prevent and treat the most common MSK conditions; Dario's behavioral health solution that optimizes access to evidence-based care; chronic condition management solutions; DarioEngage, a proprietary care management platform; and device-specific disposables test strip cartridges, lancets, and blood glucose monitoring systems. It also provides smart glucose meters; bluetooth connected blood pressure cuff; digital scales; biofeedback sensor devices; and diabetes management programs, including lifestyle changes, healthy eating, advanced tracking, and live coaching. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how DRIO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DRIO ($1.87) is undervalued by 42.93% relative to our estimate of its Fair Value price of $3.28 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
DRIO ($1.87) is significantly undervalued by 42.93% relative to our estimate of its Fair Value price of $3.28 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
DRIO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more DRIO due diligence checks available for Premium users.
Be the first to know about important DRIO news, forecast changes, insider trades & much more!
DRIO News
Valuation
DRIO fair value
Fair Value of DRIO stock based on Discounted Cash Flow (DCF)
Price
$1.87
Fair Value
$3.28
Undervalued by
42.93%
DRIO ($1.87) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
DRIO ($1.87) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
DRIO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
DRIO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.92x
Industry
31.76x
Market
31.32x
DRIO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.75x
Industry
3.93x
DRIO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DRIO's financial health
Profit margin
Revenue
$3.5M
Net Income
-$15.7M
Profit Margin
-480.5%
DRIO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
DRIO's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$106.5M
Liabilities
$38.5M
Debt to equity
0.57
DRIO's short-term assets ($56.21M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DRIO's short-term assets ($56.21M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DRIO's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
DRIO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$8.6M
Investing
-$281.0k
Financing
$204.0k
DRIO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
DRIO vs Diagnostic & Research Stocks
Dariohealth Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.